Advertisement
The update will include information about Semafore's lead productcandidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1clinical trials in solid tumors and multiple myeloma. The presentation willalso include a review of the company's pipeline advancements and businessdevelopment initiatives.
Advertisement
About SF1126
SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor thatselectively inhibits all PI3K class IA isoforms and other key members of thePI3K superfamily, including DNA-PK and mTOR. A major factor in tumorresistance to approved chemotherapy agents is thought to be the activation ofthe PI3K/PTEN pathway. As a result, it is thought that inhibiting thispathway, via SF1126, could cause the resetting of sensitivity to approvedagents and exhibit synergistic anticancer effects.
About Semafore
Semafore is a clinical stage drug discovery and development companyfocused on small molecule modulators of the PI3 kinase and PTEN cell signalingpathway, a promising target pathway for multiple disorders, including thecompany's focus - cancer. Semafore is one of the first biopharmaceuticalcompanies to focus on both PI3K and PTEN and has successfully discovered andis developing a portfolio of drug candidates addressing these targets. Formore information see the company's Web site at www.SemaforePharma.com.Contacts: Corporate Media Semafore Pharmaceuticals Inc. Russo Partners LLC Bob Marshall or Ed Jacobs David Schull or Timothy Engel (480) 278-8200 (212) 845-4271
SOURCE Semafore Pharmaceuticals Inc.